A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With BioNTech SE.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
484actual
Sites
35
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic decision made by the company
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-25 | actual | When the study began enrolling |
| Primary completion | 2025-09-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-01-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Shingles
- Herpes Zoster Infection
- Human
Interventions
- Biological: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- Biological: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
- Biological: Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Biological: Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
- Biological: Shingrix
- Biological: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Primary outcomes
what the primary-completion date above is the date OFSSA: Percentage of participants reporting local reactions
measured For 7 days after Vaccination 1 and Vaccination 2
SSA: Percentage of participants reporting systemic events
measured For 7 days after Vaccination 1 and Vaccination 2
SSA: Percentage of participants reporting adverse events
measured From Vaccination 1 to 4 weeks after last vaccination
SSA: Percentage of participants reporting serious adverse events
measured From Vaccination 1 to 6 months after the last study vaccination
SSA: Percentage of participants reporting medically attended adverse event
measured From Vaccination 1 to 6 months after the last study vaccination
SSA: Percentage of participants with abnormal hematology and chemistry laboratory assessments
measured 3 days and 1 week after each vaccination
SSA: Percentage of participants with new electrocardiogram (ECG) abnormalities
measured 3 days and 1 week after each vaccination
SSA: Percentage of participants with abnormal troponin I laboratory values
measured 3 days and 1 week after each vaccination
SSB: Percentage of participants reporting local reactions
measured For 7 days after Vaccination 1 and Vaccination 2
SSB: Percentage of participants reporting systemic events
measured For 7 days after Vaccination 1 and Vaccination 2
SSB: Percentage of participants reporting adverse events
measured From Vaccination 1 to 4 weeks after last vaccination
SSB: Percentage of participants reporting serious adverse events
measured From Vaccination 1 to 6 months after the last study vaccination
SSB: Percentage of participants reporting medically attended adverse events
measured From Vaccination 1 to 6 months after the last study vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed